Wellington Management Group
KLRS

Wellington Management Group’s Kalaris Therapeutics KLRS Stock Holding History

Wellington Management Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,975
Closed -$1.28M – 1944
2023
Q3 		$1.28M Buy
25,975
+8,703
+50% +$593K ﹤0.01% 1564
2023
Q2 		$1.35M Buy
+17,272
New +$1.64M ﹤0.01% 1557
2021
Q4 		– Sell
-11,652
Closed -$6.72M – 2312
2021
Q3 		$6.72M Buy
+11,652
New +$5.4M ﹤0.01% 1413

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Wellington Management Group's KLRS Position: Q4 2023 in Review

Wellington Management Group sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 25,975 shares — an estimated $1.28M sold.

Wellington Management Group first reported a position in KLRS in Q3 2021 and held it in 3 quarters. The position peaked at $6.72M in Q3 2021. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Wellington Management Group reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Wellington Management Group sold 25,975 Kalaris Therapeutics shares in Q4 2023, an estimated $1.28M.
  • Wellington Management Group first reported a position in Kalaris Therapeutics in Q3 2021 and held it in 3 quarters.
  • Wellington Management Group's Kalaris Therapeutics position peaked at $6.72M in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Wellington Management Group's 13F filing for Q4 2023, filed 12 Feb 2024.